Anixa Biosciences (NASDAQ:ANIX), together with partner OntoChem GmbH, has identified its first therapeutic candidate against COVID-19 and has advanced the compound into biological testing.
The compound works by disrupting the interaction
of the virus’s endoribonuclease with a host human protein that is
necessary for the virus to replicate upon infection.
https://seekingalpha.com/news/3568129-anixa-bio-up-62-premarket-on-discovery-of-first-covidminus-19-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.